Annovis Launches Multi-Year Study to Evaluate the Function and Long-Term Benefits of Buntanetap in Parkinson's Patients

Annovis Bio, Inc. (ANVS) is moving forward with an ambitious clinical research initiative designed to evaluate the function of its lead candidate Buntanetap in managing Parkinson’s disease over an extended timeframe. The pharmaceutical company plans to initiate enrollment for a 36-month open-label extension trial in January 2026, targeting approximately 500 participants at multiple U.S. medical centers.

Understanding the Clinical Need

Parkinson’s disease represents one of the most challenging neurological conditions facing modern medicine. This chronic neurodegenerative disorder progressively impairs both motor control and cognitive abilities, while available therapeutic options often deliver only incomplete symptom management. The medical community has increasingly emphasized the importance of sustained efficacy data to understand how emerging therapeutic approaches maintain their benefits across extended treatment periods and patient populations historically underrepresented in research settings.

Study Design and Patient Populations

The trial will administer once-daily oral Buntanetap at 30 mg doses throughout the 36-month period and incorporates two distinct participant groups. The first cohort comprises individuals who previously participated in earlier Buntanetap studies, allowing researchers to evaluate the function of the drug following treatment discontinuation and subsequent reinitiation. This approach provides valuable insights into symptom rebound and treatment re-response patterns.

The second cohort includes patients receiving deep brain stimulation (DBS) therapy for at least 12 months—a population traditionally excluded from most clinical trials. By evaluating the function and safety profile of Buntanetap alongside DBS, Annovis aims to generate critical data for patients using combination therapeutic strategies.

Research Objectives and Regulatory Implications

Researchers will collect skin and plasma biomarkers throughout the study period to monitor disease progression and assess whether Buntanetap demonstrates disease-modifying properties. The study design specifically aims to establish Buntanetap’s long-term safety profile, durability of therapeutic effect, and potential to slow neurological decline.

The trial represents a strategic step toward future regulatory submissions. With over 1,200 patients already exposed to the treatment across prior studies and an ongoing Phase 3 Alzheimer’s disease trial, this extension study will provide additional patient exposure data necessary to meet FDA requirements for comprehensive safety and efficacy documentation at the therapeutic dose.

Market Response

ANVS stock has demonstrated volatility over the past year, trading within a $1.11 to $5.60 range. The stock closed recent trading at $3.67 (up 1.38%), with aftermarket activity pushing the price to $3.79 (up 3.27%). Earlier Phase 3 results demonstrated that Buntanetap produced measurable improvements in both motor and non-motor symptoms while enhancing cognitive function in early-stage Parkinson’s disease patients.